# Spirax Group reports 2025 results with 5% organic revenue growth and margin progress

- Link: https://www.directorstalkinterviews.com/spirax-group-reports-2025-results-with-5-organic-revenue-growth-and-margin-progress/4121243743
- Published: 2026-03-10T07:33:35+00:00
- Author: Amilia Stone

**Spirax Group PLC** (LON:SPX) has announced its 2025 Full Year Results.

**_Strategy delivering growth well ahead of IP with margin progress; expect continued
organic growth in 2026_**

**Twelve months to 31 December**

| **Statutory (£m/p)** | **2025** | **2024** | **Reported** | 
| Revenue^(1) | 1,702.9 | 1,665.2 | 2% | 
| Operating profit | 265.4 | 304.6 |                 (13)% | 
| Operating profit margin | 15.6% | 18.3% | (270)bps | 
| Profit before taxation | 226.5 | 258.9 | (13)% | 
| Basic earnings per share | 221.7 | 259.6 | (15)% | 
| Dividend per share | 170.0 | 165.0 | 3% |

| **Adjusted**^(6) **(£m/p)** | **2025** | **2024** | **Reported** | **Organic**^(4) | 
| Revenue^(1) | 1,702.9 | 1,665.2 |                     2% |                       5% | 
| Adjusted operating profit | 339.9 | 333.9 |                     2% |                       6% | 
| Adjusted operating profit margin | 20.0% | 20.1% |           (10)bps |                30bps | 
| Adjusted profit before taxation | 301.0 | 288.2 |                  4% |  | 
| Adjusted basic earnings per share | 296.3 | 286.3 |                  3% |  | 
| Adjusted cash conversion | 89% | 87% |           200bps |  |

| **●** | Group revenue up 5% organically and well ahead of global IP^(2) of 2.1% (IP excluding China: 1.7%) | 
| **●** | STS^(3) sales up 1% organically and 3% excluding large projects in China and Korea | 
| **●** | ETS^(3) sales up 11% organically, supported by operational progress and improving Semicon^(5) demand  | 
| **●** | WMFTS^(3) sales up 6% organically, driven by Biopharm^(5) recovery and sector focus in Process Industries | 
| **●** | Group adjusted operating profit up 6%; adjusted operating margin up 30bps organically to 20% | 
| **●** | Restructuring completed with £40 million of annualised savings funding investment in growth | 
| **●** | Lower statutory operating profit and margin reflect one-off restructuring costs | 
| **●** | Improved adjusted cash conversion of 89% and leverage reduced to 1.5x; ROIC higher at 13.1% |

> **Nimesh Patel, Group Chief Executive Officer, commenting on the results said:**
> “At our 2024 Capital Markets Day, we set out our path to achieve mid-single-digit
> organic sales growth, margin progress and improving returns on capital over the
> medium term.  We are delivering on that commitment against a continuing volatile
> and uncertain macroeconomic backdrop, which is a testament to the strength of 
> our unique business model and the focused implementation of our Together for Growth
> strategy.
> “In 2025, we made good progress across the Group: STS achieved above IP organic
> growth in MRO and solution-sales globally; continued operational improvement in
> ETS drove increased throughput and sales growth; and in WMFTS, Biopharm sales 
> growth accelerated through the second half as we had expected, while Process Industries
> continued to grow well ahead of IP.  We delivered these results while also successfully
> completing a significant operational efficiency and simplification programme, 
> generating material cost savings that are funding disciplined investment in future
> growth.
> “Looking ahead to 2026, we anticipate good organic growth and further margin progress
> as we continue to build on our long track record of value creation through compounding
> growth and disciplined capital allocation.”

^(1) ‘Sales’ is used interchangeably with ‘revenue’ when describing the financial
performance of the Group

^(2) ‘IP’: Industrial Production growth (February 2026)

^(3) ‘STS’: Steam Thermal Solutions; ‘ETS’: Electric Thermal Solutions; ‘WMFTS’:
Watson-Marlow Fluid Technology Solutions

^(4) Organic measures are at constant currency and exclude contributions from current
and prior year acquisitions and disposals

^(5) ‘Semicon’: semiconductor wafer fabrication equipment manufacturers; ‘Biopharm’:
Pharmaceutical & Biotechnology sector

^(6) See Appendix to the Financial Statements for an explanation of alternative 
performance measures and reconciliation to IFRS

**_Audio webcast_**

The results presentation will be available as a live webcast from 9.30 am on the
Company’s website at http://www.spiraxgroup.com/ or via the following link: https://
edge.media-server.com/mmc/p/ya5r67dz/

A recording will be made available on the website shortly after the meeting.

[Spirax Group full year results 2025](https://www.directorstalkinterviews.com/wp-content/uploads/2026/03/Spirax-Group-full-year-results-2025.pdf)
[Download](https://www.directorstalkinterviews.com/wp-content/uploads/2026/03/Spirax-Group-full-year-results-2025.pdf)

Share on:
